<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3436AFC-51A8-400A-B98A-2F29F0933745"><gtr:id>E3436AFC-51A8-400A-B98A-2F29F0933745</gtr:id><gtr:name>Capital Medical University</gtr:name><gtr:address><gtr:line1>8 Xitou Tiao</gtr:line1><gtr:line2>Touan men wai</gtr:line2><gtr:line3>FengTai District</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3436AFC-51A8-400A-B98A-2F29F0933745"><gtr:id>E3436AFC-51A8-400A-B98A-2F29F0933745</gtr:id><gtr:name>Capital Medical University</gtr:name><gtr:address><gtr:line1>8 Xitou Tiao</gtr:line1><gtr:line2>Touan men wai</gtr:line2><gtr:line3>FengTai District</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/23D47341-B294-4027-B1ED-1C5C81B5B51E"><gtr:id>23D47341-B294-4027-B1ED-1C5C81B5B51E</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:otherNames>Louise</gtr:otherNames><gtr:surname>Rowland-Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801751"><gtr:id>491DF7DC-B5A6-4E2E-821B-35C2F010EED8</gtr:id><gtr:title>Immune mechanisms underlying delayed disease progression in HIV-1 and HIV-2 infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801751</gtr:grantReference><gtr:abstractText>In order to design an effective vaccine against HIV infection we need to know more about how the immune system can combat HIV infection in people who have controlled the virus naturally without the need for drugs. We plan to study two groups of people where there are a large number of HIV-infected subjects who have low virus levels in their blood many years after being first infected, in China and West Africa.</gtr:abstractText><gtr:technicalSummary>There remains an urgent need for an effective vaccine to prevent HIV infection. A key obstacle in vaccine design is the lack of understanding of the correlates of protective immunity against HIV infection. We propose to study potential correlates in two groups of HIV-infected subjects. The first is a plasma donor cohort in China, where infection of several hundred people appears to have occurred with a single virus strain. The second is a cohort in West Africa of HIV-2 infection, in which the majority of infected people are long-term non-progressors, but the minority who progress to disease do so in a manner identical to HIV-1 infection.</gtr:technicalSummary><gtr:fund><gtr:end>2012-08-19</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-11-20</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>364023</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Washington</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Oxford/U. Washington HIV partnership</gtr:description><gtr:id>D641F30F-54A4-4DD1-A766-862FCE5E4D4F</gtr:id><gtr:impact>Joint publications</gtr:impact><gtr:outcomeId>A65D8BF3D01-1</gtr:outcomeId><gtr:partnerContribution>We have jointly applied for NIH funding (PI Dr Grace John-Stewart) and received an R01 award, of which approximately $400,000 was in the form of a subcontract from UW to our group (1999-2005). Our collaborators have provided clinical and epidemiological support to our research studies in Nairobi and we have jointly supervised a PhD student.</gtr:partnerContribution><gtr:piContribution>We have provided training in cellular and molecular immunology techniques for Kenyan and US students, post-docs and technicians engaged in this collaboration and joint supervision of a PhD student (Jenn Slyker, completed PhD 2007).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>Gambia, Republic of the</gtr:country><gtr:department>MRC Unit, The Gambia</gtr:department><gtr:description>Oxford/Gambia HIV-2 collaboration</gtr:description><gtr:id>7AD974EC-6CFC-42F4-9D7E-8AADA42E4306</gtr:id><gtr:impact>Several joint publications. Successful completion of jointly supervised PhDs for MRC Gambia staff (Dr CO, Dr LMY).</gtr:impact><gtr:outcomeId>hgvTiiJqFBA-1</gtr:outcomeId><gtr:partnerContribution>Provision of clinical and epidemiological data on long-term HIV-2 clinical and community cohorts, with sample bank. Access to selected samples for analysis. Hosting short-term visits of students and post-docs from our group in the Gambia, provision of access to laboratory facilities.</gtr:partnerContribution><gtr:piContribution>Training of local technicians and students in the Gambia and during visits to Oxford for specialist research techniques.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Capital University of Medical Sciences</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Youan Infectious Diseases Hospital</gtr:department><gtr:description>Oxford/Youan collaboration on HIV infection</gtr:description><gtr:id>52E198DF-CCC4-4A63-A1EA-C8644A595909</gtr:id><gtr:impact>Dr YZ received his D. Phil. in 2009. Joint manuscripts have been submitted for publication. Regular collaborative visits from Beijing and Oxford researchers to the other centre.</gtr:impact><gtr:outcomeId>QgXi59BvjhZ-1</gtr:outcomeId><gtr:partnerContribution>Arranging and coordinating sample collection, storage and shipment of samples collected from a chronic HIV-1 cohort in former plasma donors in Henan province, China. Access to laboratory facilities for short-term visitors from our research group. Provision of clinical and laboratory data about the cohort (anonymised)</gtr:partnerContribution><gtr:piContribution>Funding for sample collection and clinical laboratory tests (viral load, etc). Training of nominated clinician as PhD student in Oxford. Hosting short-term and longer-term visits by clinicians and laboratory researchers to Oxford for training in specialist techniques. Joint authorship of manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Collaboration on TRIM5 alpha restriction of HIV-2 and other retroviruses</gtr:description><gtr:id>389C102E-CEF6-4378-B9C7-AF26EE225972</gtr:id><gtr:impact>joint funding proposal in preparation</gtr:impact><gtr:outcomeId>BRzqWio2E9k-1</gtr:outcomeId><gtr:partnerContribution>Expertise in TRIM 5 alpha expression and functional studies</gtr:partnerContribution><gtr:piContribution>Joint studies to identify novel polymorphisms in the TRIM 5 alpha gene and to determine their impact on the function of retroviral restriction</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HIV+ adolescents in Zimbabwe</gtr:description><gtr:id>CE62A08D-59DC-4B40-8A11-85083460BF4D</gtr:id><gtr:impact>Joint grant applications
Hosting Zimbabwean students in Oxford</gtr:impact><gtr:outcomeId>tRdQRGCXtCR-1</gtr:outcomeId><gtr:partnerContribution>Recruitment of the cohort, clinical and epidemiological expertise</gtr:partnerContribution><gtr:piContribution>Our group is studying the immunology of a cohort recruited by investigators at the LSHTM</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>school visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>9DA6ED37-847F-41FD-B0AF-9D406FC3484A</gtr:id><gtr:impact>Presentation on HIV vaccine research to around 25 intending science/medical students at local high school, which generated questions and discussion.

None reported</gtr:impact><gtr:outcomeId>J1HchVx7vuZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Alumni weekend</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>72103786-F468-4FC5-9ED4-23EBB5BD15B2</gtr:id><gtr:impact>I presented highlights of my research to the University of Oxford alumni weekend, under the title &amp;quot;Progress towards an HIV vaccine? lessons from Africa and China&amp;quot;

No major impacts</gtr:impact><gtr:outcomeId>ED98FF203C7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Weatherall Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5EFD3E25-CAB7-4EBA-9379-C764BAFBD6FD</gtr:id><gtr:impact>Talk to medical alumni of Oxford medical school about my research

Lively discussion</gtr:impact><gtr:outcomeId>kk3sJ9qiNWd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Students HIV day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>9653F608-5F56-41C7-9D6A-29B643B096B1</gtr:id><gtr:impact>50 people attended a multidisciplinary workshop on HIV research in Oxford at which I gave the keynote speech, leading to considerable discussion afterwards.

Links made with social science and public health researchers with an interest in HIV infection</gtr:impact><gtr:outcomeId>gPXZPysHcXu</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>108000</gtr:amountPounds><gtr:country>Hong Kong, Special Administrative Region of China</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Li Ka Shing Foundation award for Oxford/China collaborations</gtr:description><gtr:end>2009-06-02</gtr:end><gtr:fundingOrg>Li Ka Shing Foundation</gtr:fundingOrg><gtr:id>75D66E42-DE45-474A-8757-9F674DBBB600</gtr:id><gtr:outcomeId>6C96096CDC50</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>DNA, plasma and cells have been collected and cryopreserved from a cohort of HIV-infected former plasma donors from Henan, China, and from a control cohort of HIV negative subjects from a nearby village.</gtr:description><gtr:id>140D2B11-DC61-4751-8834-85CE10509A4D</gtr:id><gtr:impact>Led to several high impact publications.</gtr:impact><gtr:outcomeId>rZtEWQDWDSE</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>collection of blood samples from SM cohort in Henan, China</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Sequences generated from patient samples collected in China and W. Africa.</gtr:description><gtr:id>535594B7-B34A-4020-931F-16AAE0156D4F</gtr:id><gtr:impact>Sequences submitted to the HIV database in Los Alamos and now publicly available.</gtr:impact><gtr:outcomeId>fF88XoYNtNF</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HIV-1 and HIV-2 sequences</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>these are full-length HIV-2 envelope clones from W. African patients used in neutralising antibody assays and other functional studies</gtr:description><gtr:id>049ADE4F-093C-491A-A40A-313779F1B97F</gtr:id><gtr:impact>work in progress in Stuart Neil's group for tetherin antagonism</gtr:impact><gtr:outcomeId>fYfzkaN3piJ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HIV-2 envelope clones</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Full length functional envelope clones generated from HIV-2-infected patients from W. Africa, used for neutralising antibody and other functional studies.</gtr:description><gtr:id>4A9D8188-5FAF-4DE0-8B62-2EBA202CE6F4</gtr:id><gtr:impact>Studies of the ability of HIV-2 envelopes to antagonise tetherin are underway in Stuart Neil's lab (GKT).</gtr:impact><gtr:outcomeId>RbGgsaEH86E</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HIV-2 envelope clones</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>data on HIV-1 and HIV-2 sequences analysed in the Gambia have been added to the HIV database (Los Alamos) which is publicly available</gtr:description><gtr:id>EF410FC1-0EDC-494C-A10F-FAFC959E5572</gtr:id><gtr:impact>none</gtr:impact><gtr:outcomeId>MQWNo6Kz9z3</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>HIV sequences</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D158F6D0-C352-46AC-8DF9-63C3E813B99C</gtr:id><gtr:title>Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis.</gtr:title><gtr:parentPublicationTitle>Reviews in medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d4bec89b63675f4ca163786a7f26441"><gtr:id>7d4bec89b63675f4ca163786a7f26441</gtr:id><gtr:otherNames>Nyamweya S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1052-9276</gtr:issn><gtr:outcomeId>pm_15867_27_23444290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BE8E7EB-67EA-4B48-8702-816571500DF0</gtr:id><gtr:title>A 2 amino acid shift in position leads to a substantial difference in the pattern of processing of 2 HIV-1 epitopes.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9324b0be55d7eb2d2992e62ffceeb4e"><gtr:id>c9324b0be55d7eb2d2992e62ffceeb4e</gtr:id><gtr:otherNames>Culshaw A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_15867_27_22217677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AC93BF5-690F-4596-87A4-D1544B5B5CA3</gtr:id><gtr:title>Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c22f4dff265ae6494e8c07966c893b13"><gtr:id>c22f4dff265ae6494e8c07966c893b13</gtr:id><gtr:otherNames>Dong T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>X7fktvVP6EH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>503F4372-5EA8-4294-8BD9-2165CE0B35A6</gtr:id><gtr:title>Acute cytomegalovirus infection is associated with increased frequencies of activated and apoptosis-vulnerable T cells in HIV-1-infected infants.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53ec73e089aeac247def8f542613a45d"><gtr:id>53ec73e089aeac247def8f542613a45d</gtr:id><gtr:otherNames>Slyker JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15867_27_22875969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C879289-D070-4FA6-9AA9-4744696B3A95</gtr:id><gtr:title>Population dynamics of HIV-2 in rural West Africa: comparison with HIV-1 and ongoing transmission at the heart of the epidemic.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7219e699c28c45d6e339476809f7f10"><gtr:id>c7219e699c28c45d6e339476809f7f10</gtr:id><gtr:otherNames>de Silva TI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15867_27_23032414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB0BD8A0-CE36-45CA-8718-A0B42206BDE9</gtr:id><gtr:title>HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7219e699c28c45d6e339476809f7f10"><gtr:id>c7219e699c28c45d6e339476809f7f10</gtr:id><gtr:otherNames>de Silva TI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>rRqCvrcAWsQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3C2146A-C105-4DED-B3E2-B2782B1FB247</gtr:id><gtr:title>Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infection.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7219e699c28c45d6e339476809f7f10"><gtr:id>c7219e699c28c45d6e339476809f7f10</gtr:id><gtr:otherNames>de Silva TI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15867_27_23558015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF425755-20B8-44C0-8F0B-259B0F9751BF</gtr:id><gtr:title>Immune approaches for the prevention of breast milk transmission of HIV-1.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/206d12fc9d5b3cee5d6953c028e0b33a"><gtr:id>206d12fc9d5b3cee5d6953c028e0b33a</gtr:id><gtr:otherNames>Lohman-Payne B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>pm_15867_27_22454350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06590969-0534-4287-B957-951FE8165C8B</gtr:id><gtr:title>Targeting TRIM5a in HIV Cure Strategies for the CRISPR-Cas9 Era.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79413373bdcd9b31a4016ba1f5d1b8d1"><gtr:id>79413373bdcd9b31a4016ba1f5d1b8d1</gtr:id><gtr:otherNames>Weatherley DAV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5aaa4b37589c40.91315138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E9965D3-834B-46C9-A547-37C6C1E77D12</gtr:id><gtr:title>HLA-associated polymorphisms in the HIV-2 capsid highlight key differences between HIV-1 and HIV-2 immune adaptation.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7219e699c28c45d6e339476809f7f10"><gtr:id>c7219e699c28c45d6e339476809f7f10</gtr:id><gtr:otherNames>de Silva TI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5aaa4b37a5f727.10811010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56AB31BE-3559-497B-A378-4DA81B561041</gtr:id><gtr:title>The impact of HIV-1 infection and exposure on natural killer (NK) cell phenotype in Kenyan infants during the first year of life.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53ec73e089aeac247def8f542613a45d"><gtr:id>53ec73e089aeac247def8f542613a45d</gtr:id><gtr:otherNames>Slyker JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>pm_15867_27_23293640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE52EF04-0B13-49F0-B4A5-5568E37728B6</gtr:id><gtr:title>High frequency of HIV mutations associated with HLA-C suggests enhanced HLA-C-restricted CTL selective pressure associated with an AIDS-protective polymorphism.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6857832a949702b920fe517096cb5d33"><gtr:id>6857832a949702b920fe517096cb5d33</gtr:id><gtr:otherNames>Blais ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15867_27_22474021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ABAFFC0-6591-464A-89FA-18EC422448F7</gtr:id><gtr:title>HIV-2 capsids distinguish high and low virus load patients in a West African community cohort.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3094c394a39ea9ab41112106da91aea3"><gtr:id>3094c394a39ea9ab41112106da91aea3</gtr:id><gtr:otherNames>Onyango CO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>cfAjK9DMTp8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8F5D870-5A4C-463A-BE05-FDBB3B7368C2</gtr:id><gtr:title>How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses?</gtr:title><gtr:parentPublicationTitle>Immunology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bbb2be0454170f93b420b8b074fb699"><gtr:id>9bbb2be0454170f93b420b8b074fb699</gtr:id><gtr:otherNames>Makvandi-Nejad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0165-2478</gtr:issn><gtr:outcomeId>doi_55f984984dd3a5e5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D89BF61-A41A-45AF-9EA3-EF96F0F1CE92</gtr:id><gtr:title>Multilayered defense in HLA-B51-associated HIV viral control.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d895db59e431e55ec84105d0da4fab0d"><gtr:id>d895db59e431e55ec84105d0da4fab0d</gtr:id><gtr:otherNames>Zhang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>Gz5fRvVXFFd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>947BFF45-9E4E-4EBA-A9DB-DA54E08CFAC1</gtr:id><gtr:title>Highly avid, oligoclonal, early-differentiated antigen-specific CD8+ T cells in chronic HIV-2 infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0ae9c03e19152fa146debeb3e0a9814"><gtr:id>c0ae9c03e19152fa146debeb3e0a9814</gtr:id><gtr:otherNames>Leligdowicz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>Eqd7GpS8tLS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>740DB498-1110-4E1D-9156-C56F8764FF1A</gtr:id><gtr:title>Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fe865d72018863f6adc6388cb17f05c"><gtr:id>0fe865d72018863f6adc6388cb17f05c</gtr:id><gtr:otherNames>Kong R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15867_27_22933274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BD8EA46-41F0-4736-AFCC-F9E7D62DEC6B</gtr:id><gtr:title>An underestimated lentivirus model: what can HIV-2 research contribute to the development of an effective HIV-1 vaccine?</gtr:title><gtr:parentPublicationTitle>Expert review of anti-infective therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/545a8f1a39a38eb2fb8b01eef51449af"><gtr:id>545a8f1a39a38eb2fb8b01eef51449af</gtr:id><gtr:otherNames>Hodges-Mameletzis I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1478-7210</gtr:issn><gtr:outcomeId>nfGV1PAvnCq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C32D5E29-2FD8-4222-B2E2-E8FBF595DBD2</gtr:id><gtr:title>Phenotypic characterization of HIV-specific CD8+ T cells during early and chronic infant HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53ec73e089aeac247def8f542613a45d"><gtr:id>53ec73e089aeac247def8f542613a45d</gtr:id><gtr:otherNames>Slyker JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pwb83tFJFUx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A190834C-7957-4905-8EEE-ACF43BDE0672</gtr:id><gtr:title>Characterization of an HLA-C-restricted CTL response in chronic HIV infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/193c31d7dd0cbcc9e1cc55671bfe06d2"><gtr:id>193c31d7dd0cbcc9e1cc55671bfe06d2</gtr:id><gtr:otherNames>Makadzange AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>hHkjejJsMx1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>666D91C5-D850-4C0B-97D3-7A9A0EBFBC5E</gtr:id><gtr:title>Novel agents for the treatment of HIV-2 infection.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c306d45a1a18041c07012c2e6ffbf28"><gtr:id>8c306d45a1a18041c07012c2e6ffbf28</gtr:id><gtr:otherNames>Peterson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_15867_27_22301192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D166950-C94E-4559-A60F-0422FF80B738</gtr:id><gtr:title>Direct relationship between virus load and systemic immune activation in HIV-2 infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0ae9c03e19152fa146debeb3e0a9814"><gtr:id>c0ae9c03e19152fa146debeb3e0a9814</gtr:id><gtr:otherNames>Leligdowicz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>E2DCE3A8ED8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC3B4E22-1328-4596-9C0D-0779B0CC59ED</gtr:id><gtr:title>Breast milk cellular HIV-specific interferon ? responses are associated with protection from peripartum HIV transmission.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/206d12fc9d5b3cee5d6953c028e0b33a"><gtr:id>206d12fc9d5b3cee5d6953c028e0b33a</gtr:id><gtr:otherNames>Lohman-Payne B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15867_27_22948269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3ED60098-20EB-4A76-A7F5-7B9C4B3E831D</gtr:id><gtr:title>Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2-Infected Controllers.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e65eb9444356f3f384a871434a30ce40"><gtr:id>e65eb9444356f3f384a871434a30ce40</gtr:id><gtr:otherNames>Angin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5aaa4a39b21955.64246319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D02F18BD-890F-4C8D-AA01-128CBD537DB7</gtr:id><gtr:title>Influence of HLA class I and HLA-KIR compound genotypes on HIV-2 infection and markers of disease progression in a Manjako community in West Africa.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>BUWy1e5sa1C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>765DC76E-7AC4-4357-810A-2E5B3DDCBD28</gtr:id><gtr:title>A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d0c6b9b627239f85e603ce8f8de6ade"><gtr:id>3d0c6b9b627239f85e603ce8f8de6ade</gtr:id><gtr:otherNames>Zhang YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c9661f9ccc94.29914520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1093F61C-79FE-4793-984E-DE45861DF1B8</gtr:id><gtr:title>Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51f09ae31d36a289662577675db5ec78"><gtr:id>51f09ae31d36a289662577675db5ec78</gtr:id><gtr:otherNames>Jayasooriya S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>56e152172ff810.20650543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2F56DE7-DA9C-4FD0-99E1-68899F91276F</gtr:id><gtr:title>HLA-C as a mediator of natural killer and T-cell activation: spectator or key player?</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6857832a949702b920fe517096cb5d33"><gtr:id>6857832a949702b920fe517096cb5d33</gtr:id><gtr:otherNames>Blais ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>r7mZRJ1fkn9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A03C0D8-9BE8-46CF-8153-A7FFE20C47AF</gtr:id><gtr:title>Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.</gtr:title><gtr:parentPublicationTitle>Clinics in perinatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/206d12fc9d5b3cee5d6953c028e0b33a"><gtr:id>206d12fc9d5b3cee5d6953c028e0b33a</gtr:id><gtr:otherNames>Lohman-Payne B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0095-5108</gtr:issn><gtr:outcomeId>CWKyuLifFqd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9D8FE04-3B7D-42FE-8905-266E4A9829DE</gtr:id><gtr:title>The presence of prolines in the flanking region of an immunodominant HIV-2 gag epitope influences the quality and quantity of the epitope generated.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ecf15dad4439b15c78ef2845f4adcd3"><gtr:id>7ecf15dad4439b15c78ef2845f4adcd3</gtr:id><gtr:otherNames>Jallow S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>5675e556c31de</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34093BC5-E4E8-44C6-9137-0085ADEA0B06</gtr:id><gtr:title>Effect of HIV-2 infection on HIV-1 disease progression.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/292540540153f0fec29df5f22db2aecf"><gtr:id>292540540153f0fec29df5f22db2aecf</gtr:id><gtr:otherNames>de Silva T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_15867_27_23150974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0196EBE4-7E6D-4060-958A-42F947E89E32</gtr:id><gtr:title>Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7219e699c28c45d6e339476809f7f10"><gtr:id>c7219e699c28c45d6e339476809f7f10</gtr:id><gtr:otherNames>de Silva TI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>Ma7q1zV8jm6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4E45AF6-590B-4856-AA4F-1F98B58E8CB1</gtr:id><gtr:title>Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ecf15dad4439b15c78ef2845f4adcd3"><gtr:id>7ecf15dad4439b15c78ef2845f4adcd3</gtr:id><gtr:otherNames>Jallow S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>E4C5F775FCE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4E051FF-E934-4083-BF21-F06FA87B2E35</gtr:id><gtr:title>HLA correlates in a cohort of slow progressors from China: effects on HIV-1 disease progression.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d86b50b64e61e0fee42ac950781ea420"><gtr:id>d86b50b64e61e0fee42ac950781ea420</gtr:id><gtr:otherNames>Rai MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15867_27_23942057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30AB9AC1-D55C-4327-9917-1295B832B317</gtr:id><gtr:title>HIV-2: the forgotten AIDS virus.</gtr:title><gtr:parentPublicationTitle>Trends in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7219e699c28c45d6e339476809f7f10"><gtr:id>c7219e699c28c45d6e339476809f7f10</gtr:id><gtr:otherNames>de Silva TI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0966-842X</gtr:issn><gtr:outcomeId>FBDB9A1DFBA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3406A566-DC90-40D7-BAC2-623B0B41F0EF</gtr:id><gtr:title>A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e4edb94329682eb44ba4663201c354"><gtr:id>54e4edb94329682eb44ba4663201c354</gtr:id><gtr:otherNames>Gottlieb GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>BFF9691F06C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F61CB517-75EA-4EFA-B8BC-036342D88C8D</gtr:id><gtr:title>Presence of a multidrug-resistance mutation in an HIV-2 variant infecting a treatment-naive individual in Caio, Guinea Bissau.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ecf15dad4439b15c78ef2845f4adcd3"><gtr:id>7ecf15dad4439b15c78ef2845f4adcd3</gtr:id><gtr:otherNames>Jallow S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>FC1064EBB7B</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801751</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>